28 diciembre 2016

PM01183 ... Actualización de la Fase III Pulmón .

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial) .
Sponsor: PharmaMar .

Resultado de imagen de estados unidos pulmonView of NCT02566993 on 2016_12_25

ClinicalTrials Identifier: NCT02566993

Updated: 2016_12_25 .

Health Authority: United States: Food and Drug Administration .

Lebanon: Ministry of Public Health .

Hungary: National Institute of Pharmacy .

Canada: Health Canada .

Czech Republic: State Institute for Drug Control .

Austria: Austrian Federal Office for Safety in Health Care .

Belgium: Federal Agency for Medicines and Health Products, FAMHP .

Brazil: National Health Surveillance Agency .

Portugal: INFARMED, National Authority of Medicines and Health Products, IP .

Spain: Agencia Española de Medicamentos y Productos Sanitarios .

Greece: National Organization of Medicines .

United Kingdom: Medicines and Healthcare Products Regulatory Agency .

Germany: Federal Institute for Drugs and Medical Devices .

Italy: The Italian Medicines Agency .

Bulgaria: Bulgarian Drug Agency .